

Validity and usefulness of a single-item measure of patient effects of cancer therapy

Cancer

124, 991-997

DOI: [10.1002/cncr.31133](https://doi.org/10.1002/cncr.31133)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03). Breast Cancer Research and Treatment, 2018, 169, 537-548.	2.5	58
2	Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events: Methods for item selection in industry-sponsored oncology clinical trials. Clinical Trials, 2018, 15, 616-623.	1.6	24
3	Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2018, 19, 1404-1416.	10.7	105
4	Important Group Differences on the Functional Assessment of Cancer Therapyâ€œKidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma. Value in Health, 2018, 21, 1413-1418.	0.3	7
5	Proactive use of PROMs in ovarian cancer survivors: a systematic review. Journal of Ovarian Research, 2019, 12, 63.	3.0	17
6	Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncology, The, 2019, 20, 1518-1530.	10.7	69
7	Further content validation of the 18-item NCCN/FACT Ovarian Symptom Index and its Disease Related Symptom-Physical (DRS-P) subscale for use in advanced ovarian cancer clinical trials. Health and Quality of Life Outcomes, 2019, 17, 185.	2.4	5
8	<p>Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) Medication Adherence Scale (PMAS)</p>. Patient Preference and Adherence, 2020, Volume 14, 971-983.	1.8	13
9	Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 971-982.	2.2	1
10	Validation of brief symptom indexes among patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the ECOGâ€œACRIN Cancer Research Group (E1302). Cancer Medicine, 2020, 9, 8884-8894.	2.8	5
11	Health-related quality Of Life n patients with advanced Soft Tissue sarcomas treated with Chemotherapy (The HOLISTIC study): protocol for an international observational cohort study. BMJ Open, 2020, 10, e035171.	1.9	8
12	Exploration of baseline patient-reported side effect bother from cancer therapy. Clinical Trials, 2020, 17, 332-337.	1.6	8
13	The FCRâ€œ1: Initial validation of a singleâ€œitem measure of fear of cancer recurrence. Psycho-Oncology, 2020, 29, 788-795.	2.3	23
14	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2020, 26, 2506-2514.	7.0	20
15	Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review. Journal of the National Cancer Institute, 2021, 113, 532-542.	6.3	25
16	Inferences About Drug Safety in Phaseâ€œIII Trials in Oncology: Examples From Advanced Prostate Cancer. Journal of the National Cancer Institute, 2021, 113, 553-561.	6.3	12
17	Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 632-642.	10.7	40
18	Patient Global Impression of Benefitâ€œRisk (PGI-BR): Incorporating Patientsâ€œ™ Views of Clinical Benefitâ€œRisk into Assessment of New Medicines. Drug Safety, 2021, 44, 1059-1072.	3.2	0

#	ARTICLE	IF	CITATIONS
19	Applying the Toxicity Index to Patient-Reported Symptom Data: An Example Using the European Organization for Research and Treatment of Cancer Colorectal Cancerâ€”Specific Quality of Life Questionnaire. <i>Clinical Therapeutics</i> , 2021, 43, 1245-1252.	2.5	1
20	Understanding Treatment Tolerability in Older Adults With Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2150-2163.	1.6	33
21	Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 158-168.	0.4	6
22	Application of Gold Nanoparticle-Based Materials in Cancer Therapy and Diagnostics. <i>ChemEngineering</i> , 2021, 5, 69.	2.4	17
23	Association Between Physician- and Patient-Reported Symptoms in Patients Treated With Definitive Radiation Therapy for Locally Advanced Lung Cancer in a Statewide Consortium. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 942-950.	0.8	7
24	An Exploratory Analysis of the â€œWas It Worth It?â€”Questionnaire as a Novel Metric to Capture Patient Perceptions of Cancer Treatment. <i>Value in Health</i> , 2022, 25, 1081-1086.	0.3	9
25	Reconsidering tolerability of cancer treatments: opportunities to focus on the patient. <i>Supportive Care in Cancer</i> , 2022, 30, 3661-3663.	2.2	4
26	The value of patient-reported outcomes in early-phase clinical trials. <i>Nature Medicine</i> , 2022, 28, 18-20.	30.7	28
28	Validity of a single-item indicator of treatment side effect bother in a diverse sample of cancer patients. <i>Supportive Care in Cancer</i> , 2022, 30, 3613-3623.	2.2	5
29	Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 292-303.	10.7	42
30	The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: Guidance for Use in Research and Clinical Practice. , 2022, , 79-104.		5
31	Assessing the Impact of Decision Aid Use on Post Prostatectomy Patient Reported Outcomes. <i>Urology</i> , 2022, , .	1.0	1
32	Frequency of Symptomatic Adverse Events in Rheumatoid Arthritis: An Exploratory Online Survey. <i>Journal of Rheumatology</i> , 2022, 49, 998-1005.	2.0	5
33	Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 473-482.	1.2	20
34	Using Patient-Reported Outcomes in Dose-Finding Oncology Trials: Surveys of Key Stakeholders and the National Cancer Research Institute Consumer Forum. <i>Oncologist</i> , 2022, 27, 768-777.	3.7	5
35	Stress Management Interventions to Facilitate Psychological and Physiological Adaptation and Optimal Health Outcomes in Cancer Patients and Survivors. <i>Annual Review of Psychology</i> , 2023, 74, 423-455.	17.7	17
36	Patient-reported tolerability of adjuvant ipilimumab (3 or 10Âµg/kg) versus high-dose interferon alfa-2b for resected high-risk stage IIIâ€”IV melanoma in phase III trial E1609. <i>Quality of Life Research</i> , 0, , .	3.1	0
37	Feasibility of a new electronic patient-reported outcome (ePRO) system for an advanced therapy clinical trial in immune-mediated inflammatory disease (PROmics): protocol for a qualitative feasibility study. <i>BMJ Open</i> , 2022, 12, e063199.	1.9	2

#	ARTICLE	IF	CITATIONS
38	Comparison of Simple-Summed Scoring and Toxicity Index Scoring of Symptom Bother in the NSABP B-30 Clinical Trial. <i>Applied Research in Quality of Life</i> , 0, , .	2.4	0
39	Patients'™ and health-care professionals'™ perspectives on adverse drug reaction burden attributed to the use of biological DMARDs: a qualitative study. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 417-424.	2.4	1
40	How do patients interpret and respond to a single-item global indicator of cancer treatment tolerability?. <i>Supportive Care in Cancer</i> , 2023, 31, .	2.2	0
41	Parental self-efficacy managing a child's™ medications and treatments: adaptation of a PROMIS measure. <i>Journal of Patient-Reported Outcomes</i> , 2023, 7, .	1.9	1
42	Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial. <i>European Journal of Cancer</i> , 2023, 187, 164-173.	2.8	4
43	Psychometrics of patient-reported bother from side effects of treatment single-items in industry-sponsored oncology trials. <i>Quality of Life Research</i> , 0, , .	3.1	0
44	Real-world patient-reported outcomes and concordance between patient and physician reporting of side effects across lines of therapy in multiple myeloma within the USA. <i>Supportive Care in Cancer</i> , 2023, 31, .	2.2	0
45	International Society for Quality of Life Research commentary on the US Food and Drug Administration draft guidance for industry on core patient-reported outcomes in cancer clinical trials. <i>Quality of Life Research</i> , 2023, 32, 2155-2163.	3.1	0
46	Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	0
47	Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	0
48	Development and usability testing of an electronic patient-reported outcome (ePRO) solution for patients with inflammatory diseases in an Advanced Therapy Medicinal Product (ATMP) basket trial. <i>Journal of Patient-Reported Outcomes</i> , 2023, 7, .	1.9	2
49	Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131. <i>Cancer</i> , 2024, 130, 1747-1757.	4.1	0
50	Administering selected subscales of patient-reported outcome questionnaires to reduce patient burden and increase relevance: a position statement on a modular approach. <i>Quality of Life Research</i> , 2024, 33, 1075-1084.	3.1	0
51	Problem resolution scale: A single-item instrument for easily assessing clinical improvement. <i>Journal of Marital and Family Therapy</i> , 2024, 50, 477-494.	1.1	0